Medspresso Launches Handcrafted Delights, CBD Infused Functional Foods | M2Bio Sciences (WUHN)

CAPE TOWN, SA / ACCESSWIRE / October 26, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan”…

A new Chief Operating Officer for M2Bio Science inc | WUHN

CAPE TOWN, SA / ACCESSWIRE / October 5, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or…

Revive Therapeutics finalizes five clinical sites for their FDA COVID-19 Phase 3

Revive Therapeutics | CSE: RVV USA: RVVTF Today, Revive Therapeutics issued an important press release to…

Investors: If you like Compass Pathways you will love M2Bio Sciences.

For several weeks now, no one can dispute that the psychedelics market is one of the…

M2Bio Sciences | WUHN enters cannabis production and projects nearly $10M (us) in revenue for the first year

M2Bio Sciences, Inc | WUHN on OTC Earlier this week, M2Bio Sciences Inc | WUHN, which is already…

A centerpiece in the psychedelics market : Revive Therapeutics

Last week, the booming psychedelic market saw the first psychedelic company to surpass $1 billion in…

Wuhan General Group Corporate Update on Tsime Pharmaceuticals Acquisition

CAPE TOWN, SA / ACCESSWIRE / September 22, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the…

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

TORONTO, Sept. 16, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

TORONTO, Sept. 02, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

M2Bio Sciences | An opportunity in the psychedelic and cannabinoids market

M2Bio Sciences, Inc | WUHN on OTC Who are M2Bio Sciences ? M2Bio Sciences | WUHN through its…

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…